SCHEMBL3006243

SCHEMBL3006243

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3ccc(C)cc3)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
PKM P14618 3/20 0.52
USP2 O75604 1/20 0.49
MAPT P10636 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 2/20 0.46
TP53 P04637 2/20 0.46
GFER P55789 1/20 0.46
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
HSD11B1 P28845 1/20 0.44
GBA1 P04062 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015412 0.92 MEN1 (0.54) MEN1KMT2APKMUSP2MAPT
SCHEMBL3013485 0.92 MAPT (0.58) MEN1KMT2APKMUSP2MAPT
SCHEMBL3005294 0.92 TP53 (0.56) KMT2APKMUSP2MAPTRECQL
SCHEMBL3022582 0.91 ALDH1A1 (0.48) MEN1KMT2APKMUSP2MAPT
SCHEMBL3012360 0.90 HSD11B1 (0.48) MEN1KMT2AUSP2MAPTRECQL
SCHEMBL3005487 0.90 USP2 (0.47) MEN1KMT2APKMUSP2MAPT
SCHEMBL3015038 0.90 HSD17B10 (0.57) PKMUSP2MAPTRECQLHSD17B10
SCHEMBL3005087 0.89 MAPT (0.46) MEN1KMT2APKMUSP2MAPT
SCHEMBL3014870 0.88 HSD11B1 (0.49) MEN1KMT2APKMALDH1A1SMN1; SMN2
SCHEMBL3012688 0.88 USP2 (0.51) KMT2APKMUSP2MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MEN1 454/4885KMT2A 2680/4885PKM 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.